Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Welireg is intended for adults with VHL disease who need therapy for associated renal cell carcinoma (RCC), central nervous ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...

Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

Pregnancy brings dramatic changes to a woman's vascular system, with potentially serious health implications for both mother ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Atherosclerosis, a disease characterized by the accumulation of lipids and inflammatory cells in the arterial wall, is a ...